GSK plc’s GSK Specialty Medicines segment includes medicines that prevent and treat diseases like HIV, cancer, asthma and ...

GSK announces US FDA accepts application to review expanded use of RSV vaccine, Arexvy for adults 18-49 at increased risk: London, UK Wednesday, July 16, 2025, 14:00 Hrs [IST] GSK ...

GSK plc (GSK) said on Monday that its application for extending the use of its respiratory syncytial virus (RSV) vaccine Arexvy to adults aged 18-49 who are at increased risk of contracting the ...

London: GSK plc has announced that the US Food and Drug Administration (FDA) has accepted for review an application to extend ...

GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine ...

Sanofi and Regeneron, AstraZeneca, Roche’s Genentech and GSK have provided support for the Living Well with COPD educational ...

Biologics like mepolizumab are providing renewed optimism for those affected by COPD.” According to the release — issued by GSK, the drug’s maker — the approval was based on two clinical ...

GSK (LSE:GSK) recently received FDA approval for Nucala for COPD treatment, potentially enhancing its market presence. Meanwhile, the Committee for Medicinal Products for Human Use recommended ...

GSK plc (NYSE:GSK) has strengthened its market outlook following major regulatory milestones.The U.S. FDA’s recent approval of Nucala for chronic obstructive pulmonary disease (COPD) and a ...

Merck has pulled off another acquisition which fits in its “sweet spot,” as described by CEO Rob Davis, paying $10 billion ...

Dietary approaches are shaping up as a key aspect of chronic obstructive pulmonary disease (COPD) management.

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud.You can reach Elaine on Signal at elaineywchen.70.